PUBLIC RELEASE DATE:

2-Dec-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, December 2, 2014--The challenges in providing psychotherapy to individuals with autism spectrum disorders (ASD) who also are struggling with their gender identity are explored in two case studies of high-functioning persons with diagnoses of ASD and gender dysphoria (GD). The authors describe the unique complexities presented by these two diagnoses and offer suggested techniques for helping these individuals explore their gender identities in an article in LGBT Health, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the LGBT Health website until January 2, 2015.

New York, NY-based psychotherapist Laura A. Jacobs, LCSW, and coauthors from New York University and private practice explain why characteristics of ASD, such as the limited ability to express feelings, difficulty with social interaction and impaired theory of mind, as well as the intolerance of ambiguity, may present special difficulties for gender identity formation in persons with GD. However, in the article "Gender Dysphoria and Co-Occurring Autism Spectrum Disorders: Review, Case Examples, and Treatment Considerations," the authors suggest that high-functioning individuals with ASDs and GD can be good candidates for gender transition and can benefit from it.

"While much has been written recently on the co-occurrence of GD and ASDs, few case histories or papers discussing treatment have been published to date, gaps that this article addresses," says Editor-in-Chief William Byne, MD, PhD, Icahn School of Medicine at Mount Sinai, New York, NY. "The article also underscores that while the presence of an autism spectrum disorder poses particular issues that must be addressed, it does not preclude gender transition."

###

About the Journal

Spanning a broad array of disciplines LGBT Health, published quarterly online with Open Access options and in print, brings together the LGBT research, health care, and advocacy communities to address current challenges and improve the health, well-being, and clinical outcomes of LGBT persons. The Journal publishes original research, review articles, clinical reports, case studies, legal and policy perspectives, and much more. Complete tables of content and a sample issue may be viewed on the LGBT Health website.

About the Publisher

View post:

Combination of autism spectrum disorder and gender nonconformity presents unique challenges

19 hours ago by Bendta Schroeder

Before DNA can be transcribed into RNA, an early step in turning the genetic template into protein, the nucleus must first assemble a molecular machine called the pre-initiation complex (PIC), capable of unzipping the double helix and loading the DNA onto the transcription enzyme.

The PIC's dozens of parts are scattered throughout a dense nucleus, packed with DNA, proteins, and other biomolecules. Transcription factors and enzymes must find their way to the transcription site, driven by weak and transient interactions, to be assembled into a living, working machine. The assembly can happen in a matter of seconds.

Weak and transient interactions are thought to propel, not just transcription, but the majority of vital cell processes. In these interactions, biomolecules join and disband easily, allowing them to act collectively and quickly in response to the needs of the cell. But exactly how these interactions work is a mystery.

Ibrahim Ciss, assistant professor of physics, wants to solve this mystery, molecule by molecule, in living cells, in real time.

"This is probably one of the most spectacular examples in nature where the interactions of individual biomolecules give rise to something we don't yet understandthe emergence of life," Ciss says.

Transcription, molecule by molecule

For Ciss to follow transcription as it unfolds, he would have to circumvent the limitations of conventional techniques for studying biomolecules. Biochemical techniques that isolate molecules in test tubes or label them in fixed cells destroy the conditions that make weak and transient interactions possible. Light microscopy can preserve those conditions, but most biomolecules are too small and interact too closely to be distinguished with the light diffraction limit of 200 nanometers.

Instead, Ciss uses tools from physics to illuminate the transcription process at high resolution. For example, he adapted a new fluorescent imaging technique called photoactivation localization microscopy (PALM). PALM activates fluorescent tagging proteins at random and then applies a statistical algorithm to determine the exact location of each protein with nanometer-accuracy within the pixel of light. When Ciss repeats the process at high speed and volume, he can map the precise location of tagged biomolecules as they cluster at a transcription site or trace the path of a single transcription factor as it moves across the nucleus. Furthermore, by developing a temporal correlation method coupled with PALM, called tcPALM, Ciss can get direct access to the clustering dynamics for the first time.

Recently, Ciss used tcPALM to show that the transcriptional enzyme RNA Polymerase II (Pol II) clusters for just a few seconds as transcription begins. The result is surprising, given that it takes several minutes for a full RNA sequence to be synthesized. When Ciss suppressed and then reactivated transcription just before imaging, he observed Pol II clustering at unusually high concentrations. When he blocked Pol II from escaping the promoter and transcribing the DNA, the cluster of Pol II around the promoter didn't dissipate.

Read the original:

Unraveling the mystery of DNA transcription, one molecule at a time

8 hours ago Streptococcus pyogenes is one of the bacteria in which the HZI scientists have studied the CRISPR-Cas system. Credit: HZI / M. Rohde

Genome engineering with the RNA-guided CRISPR-Cas9 system in animals and plants is changing biology. It is easier to use and more efficient than other genetic engineering tools, thus it is already being applied in laboratories all over the world just a few years after its discovery. This rapid adoption and the history of the system are the core topics of a review published in the renowned journal Science. The review was written by the discoverers of the system Prof. Emmanuelle Charpentier, who works at the Helmholtz Centre for Infection Research (HZI) and is also affiliated to the Hannover Medical School and Ume University, and Prof. Jennifer Doudna from the University of California, Berkeley, USA.

Many diseases result from a change of an individual's DNA - the letter code that genes consist of. The defined order of the letters within a gene usually codes for a protein. Proteins are the workforce of our body and responsible for almost all processes needed to keep us running. When a gene is altered, its protein product may lose its normal function and disorders can result. "Making site-specific changes to the genome therefore is an interesting approach to preventing or treating those diseases", says Prof Emmanuelle Charpentier, head of the HZI research department "Regulation in Infection Biology". Due to this, ever since the discovery of the DNA structure, researchers have been looking for a way to alternate the genetic code.

First techniques like zinc finger nucleases and synthetic nucleases called TALENs were a starting point but turned out to be expensive and difficult to handle for a beginner. "The existing technologies are dependent on proteins as address labels and customizing new proteins for any new change to introduce in the DNA is a cumbersome process", says Charpentier. In 2012, while working at Ume University, she described what is now revolutionising genetic engineering: the CRISPR-Cas9 system.

It is based on the immune system of bacteria and archaea but is also of value in the laboratory. CRISPR is short for Clustered Regularly Interspaced Palindromic Repeats, whereas Cas simply stands for the CRISPR-associated protein. "Initially we identified a novel RNA, namely tracrRNA, associated to the CRISPR-Cas9 system, which we published in 2011 in Nature. We were excited when Krzysztof Chylinski from my laboratory subsequently confirmed a long term thinking: Cas9 is an enzyme that functions with two RNAs", says Charpentier.

Together the system has the ability to detect specific sequences of letters within the genetic code and to cut DNA at a specific point. In this process the Cas9 protein functions as the scissors and an RNA snippet as the address label ensuring that the cut happens in the right place. In collaboration with Martin Jinek and Jennifer Doudna, the system could be simplified to use it as a universal technology. Now the user would just have to replace the sequence of this RNA to target virtually any sequence in the genome.

After describing the general abilities of CRISPR-Cas9 in 2012 it was shown in early 2013 that it works as efficiently in human cells as it does in bacteria. Ever since, there has been a real hype around the topic and researchers from all over the world have suggested new areas in which the new tool can be used. The possible applications extend from developing new therapies for genetic disorders caused by gene mutations to changing the pace and course of agricultural research in the future all the way to a possible new method for fighting the AIDS virus HIV.

"The CRISPR-Cas9 system has already breached boundaries and made genetic engineering much more versatile, efficient and easy", Charpentier says. "There really does not seem to be a limit in the applications."

Explore further: RCas9: A programmable RNA editing tool

Viruses cannot only cause illnesses in humans, they also infect bacteria. Those protect themselves with a kind of 'immune system' which simply put consists of specific sequences in the genetic material ...

More here:

Revolutionizing genome engineering: Review on history and future of the CRISPR-Cas9 system published

Genome engineering with the RNA-guided CRISPR-Cas9 system in animals and plants is changing biology. It is easier to use and more efficient than other genetic engineering tools, thus it is already being applied in laboratories all over the world just a few years after its discovery. This rapid adoption and the history of the system are the core topics of a review published in the journal Science. The review was written by the discoverers of the system Prof. Emmanuelle Charpentier, who works at the Helmholtz Centre for Infection Research (HZI) and is also affiliated to the Hannover Medical School and Ume University, and Prof. Jennifer Doudna from the University of California, Berkeley, USA.

Many diseases result from a change of an individual's DNA -- the letter code that genes consist of. The defined order of the letters within a gene usually codes for a protein. Proteins are the workforce of our body and responsible for almost all processes needed to keep us running. When a gene is altered, its protein product may lose its normal function and disorders can result. "Making site-specific changes to the genome therefore is an interesting approach to preventing or treating those diseases," says Prof Emmanuelle Charpentier, head of the HZI research department "Regulation in Infection Biology." Due to this, ever since the discovery of the DNA structure, researchers have been looking for a way to alternate the genetic code.

First techniques like zinc finger nucleases and synthetic nucleases called TALENs were a starting point but turned out to be expensive and difficult to handle for a beginner. "The existing technologies are dependent on proteins as address labels and customizing new proteins for any new change to introduce in the DNA is a cumbersome process," says Charpentier. In 2012, while working at Ume University, she described what is now revolutionising genetic engineering: the CRISPR-Cas9 system.

It is based on the immune system of bacteria and archaea but is also of value in the laboratory. CRISPR is short for Clustered Regularly Interspaced Palindromic Repeats, whereas Cas simply stands for the CRISPR-associated protein. "Initially we identified a novel RNA, namely tracrRNA, associated to the CRISPR-Cas9 system, which we published in 2011 in Nature. We were excited when Krzysztof Chylinski from my laboratory subsequently confirmed a long term thinking: Cas9 is an enzyme that functions with two RNAs," says Charpentier.

Together the system has the ability to detect specific sequences of letters within the genetic code and to cut DNA at a specific point. In this process the Cas9 protein functions as the scissors and an RNA snippet as the address label ensuring that the cut happens in the right place. In collaboration with Martin Jinek and Jennifer Doudna, the system could be simplified to use it as a universal technology. Now the user would just have to replace the sequence of this RNA to target virtually any sequence in the genome.

After describing the general abilities of CRISPR-Cas9 in 2012 it was shown in early 2013 that it works as efficiently in human cells as it does in bacteria. Ever since, there has been a real hype around the topic and researchers from all over the world have suggested new areas in which the new tool can be used. The possible applications extend from developing new therapies for genetic disorders caused by gene mutations to changing the pace and course of agricultural research in the future all the way to a possible new method for fighting the AIDS virus HIV.

"The CRISPR-Cas9 system has already breached boundaries and made genetic engineering much more versatile, efficient and easy," Charpentier says. "There really does not seem to be a limit in the applications."

Story Source:

The above story is based on materials provided by Helmholtz Centre for Infection Research. Note: Materials may be edited for content and length.

Go here to read the rest:

Revolutionizing genome engineering

GENETIC ENGINEERING: Cow/Pig CREATURE will be on your DINNER PLATE
Hybrid cow/pig meat is threatening cities on a global level. Please watch, share, and write your congress persons. If this scientific experimentation on FOOD...

By: Total Vids Lists

Visit link:

GENETIC ENGINEERING: Cow/Pig CREATURE will be on your DINNER PLATE - Video

November 29, 2014

"Spider silk' is stronger than conventional silk and could be used for textiles

TOKYO: Japanese scientists have developed through genetic engineering using genes from spiders and silkworms a super resistant silk which could be used for textiles as well as in the surgical field, media reported on Friday.

Known as Spider Silk, which is stronger and smoother than conventional silk, it has been developed by researchers at Shinshu University, the Asahi daily newspaper reported.

Masao Nakagaki from the Faculty of Textile Science and Technology was the first person, in 2007, to implant spider genes in silkworms, resulting in the production of silk which had some components of spider webs.

Several years of research has now led to the development of spider silk which has less than 20 per cent of the components of spider webs.

Several prototypes of socks have also been manufactured using this new material.

It is expected that the hybrid silk would be used in the textile industry, and for manufacturing surgical threads and artificial blood vessels.

The university reached an agreement with the local government to commercially produced the hybrid silk.

Both institutions have decided to collaborate in areas of industrial development, training of personnel, academic research and use of facilities for commercial production of the silk, according to Asahi.

Read the original:
Scientists develop hybrid silk using spider genes

Islam, Genetic Engineering and Bioethics /
Interview with Dr. Rana Dajani.

By: TVIslamScience

See the rest here:

Islam, Genetic Engineering and Bioethics / - Video

Genetic Engineering: The Super Banana
Project for APES. By Sydney Hsueh and Jenny Lee.

By: Sydney Hsueh

View post:

Genetic Engineering: The Super Banana - Video

Advanced CRISPR Cas9 Genetic Engineering
The CRISPR Cas9 system has been harnessed to create a simple, RNA programmable method to mediate genome editing in mammalian cells, and can be used to generate gene knockouts (via ...

By: William Orfanos

Here is the original post:

Advanced CRISPR Cas9 Genetic Engineering - Video

Catholic Edge Genetic Engineering HD
Video By: Austin Riordan.

By: Anna Landis

Here is the original post:

Catholic Edge Genetic Engineering HD - Video

PUBLIC RELEASE DATE:

24-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 24, 2014--Genetically engineered pigs, minipigs, and microminipigs are valuable tools for biomedical research, as their lifespan, anatomy, physiology, genetic make-up, and disease mechanisms are more similar to humans than the rodent models typically used in drug discovery research. A Comprehensive Review article entitled "Current Progress of Genetically Engineered Pig Models for Biomedical Research," describing advances in techniques to create and use pig models and their impact on the development of novel drugs and cell and gene therapies, is published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available on the BioResearch Open Access website at http://online.liebertpub.com/doi/full/10.1089/biores.2014.0039.

Gkhan Gn and Wilfried Kues, Friedrich-Loeffler-Institute (Neustadt, Germany), Istanbul Technical University, and Istanbul University Faculty of Veterinary Medicine (Turkey), discuss the technologies that have made it possible to develop transgenic pig models of human diseases, such as targeted gene transfer and genome sequencing. The authors review current progress in creating transgenic pig models for cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, ophthalmology, and xenotransplantation. These models will enable researchers to study disease processes, identify new drug targets, test novel cell therapies to restore diseased tissues and organs, and assess methods to correct or replace mutated genes.

"This review provides an excellent update of recent progress in the field of pig transgenics for biomedical research," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland.

###

About the Journal

BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website at http://www.liebertpub.com/biores.

About the Publisher

More:

New treatments for cancer, diabetes, and heart disease -- you may have a pig to thank

With an MBA from the University of Chicago (2006) and an MSc from the Compigne University of Technology (1997), David Del Bourgo has combined education in management and biomedical engineering. He has acquired 17 years of experience in marketing and sales development within the healthcare industry.

Before joining Genomic Vision, David Del Bourgo was VP Sales and Marketing at Theraclion, which specializes in therapeutic ultrasound equipment. After joining the company in 2009, he instigated Theraclions marketing strategy, developed the network of key opinion leaders and deployed the direct and indirect sales of an innovative echotherapy solution, which established the company as a major player in the treatment of tumors by ultrasound.

From 2006 to 2009, David was Director of Corporate Development and Marketing at Orbotech, a NASDAQ-listed Israeli electronics company, where he notably contributed to the growth of their medical division and led the acquisition of a Danish company specializing in nuclear cardiology (turnover of $30 million). His other positions have included Manager in Strategic Consulting at Advention Business Partners (2005-2006) and various positions at General Electric Healthcare, where he was initially a researcher (1997) before being appointed International Product Marketing Manager (2001-2003).

At Genomic Vision, Davids mission has begun with the setting up of a Sales and Marketing team, which is already operational, consisting of product specialists and a field team whose aim will be to promote the Companys innovative genetic tests among the main European diagnostic centers.

Aaron Bensimon, Genomic Visions co-founder and Chairman, says: We are very pleased to be able to count on a manager with such experience at Genomic Vision. David and his team are highly driven by their objective of deploying our international marketing strategy. His expertise and knowledge of the sector represent real assets in identifying sales opportunities for the genetic tests we are developing, and notably those targeting breast and colon cancer, which are scheduled to be launched in 2015.

Next financial press release

ABOUT GENOMIC VISION A spinoffof the Institut Pasteur, Genomic Vision is a molecular diagnostics company specialized in developing diagnostic tests for genetic diseases and cancers. Using molecular combing, an innovative technology that allows the direct visualization of individual DNA molecules, Genomic Vision detects quantitative and qualitative variations in the genome that are at the origin of numerous serious pathologies. Having benefited from the financial support of the Institut Pasteur, SGAM AI, Vesalius Biocapital and Quest Diagnostics, the Company is developing a solid portfolio of tests that notably target breast cancer and cancer of the colon. Since 2013, the Company has marketed the CombHeliX FSHD test for identifying a myopathy that is difficult to detect, Facio-scapulo-humeral dystrophy (FSHD), in the United States thanks to a strategic alliance with Quest Diagnostics, the American leader in diagnostic laboratory tests, and in France.

ABOUT MOLECULAR COMBING DNA molecular combing technology considerably improves the structural and functional analysis of DNA molecules. DNA fibers are stretched out on glass slides, as if combed, and uniformly aligned over the whole surface. It is then possible to identify genetic anomalies by locating genes or specific sequences in a patients genome using genetic markers, an approach developed by Genomic Vision and patented under the name Genomic Morse Code. This exploration of the entire genome at high resolution via a simple analysis enables the direct visualization of genetic anomalies that are undetectable by other technologies.

For further information, please go to http://www.genomicvision.com

Read more:

Genomic Vision Appoints David Del Bourgo as Head of Sales and Marketing

Genetic Engineering Mash Up

By: Jon Peret

See original here:
Genetic Engineering Mash Up - Video

Might a GMO potato really be a better potato than can win over opponents of genetic engineering and feed the French fry minions? Image: J.R. Simply.

J.R. Simplot won federal approval for a genetically modified potato on Nov. 7, and although it is a major supplier of french fries to McDonald's , don't worry about some GMO spud showing up in your Happy Meal. The fast-food chain says it has no plans on adopting it anytime soon.

But that might not be the case for long.

Simplot says that because its new potato is made from genes derived from potatoes themselves and not bacteria or genes from other species, thus creating some sort of Frankenfood, it doesn't rise to the same level of concern activists would have over some crops, or when they thwarted Monsanto's effort to propagate a GMO potato in the 1990's.

Back then, Monsanto got the FDA to approve its New Leaf potatoes that were resistant to disease and insects through the development of a synthetic version of the bacillus thuringiensis bacterium, or Bt.

After initial acclaim, the biotech charged high premiums for its seed, which limited adoption, and then ultimately went nowhere when McDonald's and the Frito-Lay division of PepsiCo were cowed by anti-GMO activists into rejecting them. J.R. Simplot, an early adopter of the GMO potato, instructed its farmers not to plant them. Monsanto eventually stopped developing the potato in 2001.

Simplot's new Innate potatoes was developed to be especially beneficial to fast-food restaurants that sell lots of french fries. It's a little science-y, but it's important to understanding what Simplot is doing.

When potatoes and other starchy foods like bread (and even coffee!) are processed at high temperatures, such as when they're deep-fried, a carcinogenic chemical compound called acrylamide if formed.

View original post here:
A GMO Potato Is Approved, But Will Anyone Buy It?

UNIV 100 Genetic Engineering

By: Zoe Murray

Originally posted here:
UNIV 100 Genetic Engineering - Video

6.5.1 Genetic Engineering

By: ZogScience

Originally posted here:

6.5.1 Genetic Engineering - Video

Genetic Engineering Recast
English 1001 recast project.

By: Brent Ufkes

Continue reading here:

Genetic Engineering Recast - Video

BIOLOGY: Genetic Engineering - Robin Hesketh
Good News for cancer therapy. Trials show genetic engineering of T-cells in the treatment of B-Cell Acute Lymphocitic Leukemia works.

By: Hay Levels

Originally posted here:

BIOLOGY: Genetic Engineering - Robin Hesketh - Video

PUBLIC RELEASE DATE:

20-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 20, 2014-Women are more sensitive to the effects of cocaine and more susceptible to cocaine abuse than men. Cocaine's ability to disrupt a woman's estrus cycle may explain the sex differences in cocaine addiction, and new evidence that caffeine may be neuroprotective and able to block cocaine's direct effects on the estrus cycle reveals novel treatment possibilities, according to an article published in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Caffeine Research website at http://online.liebertpub.com/doi/full/10.1089/jcr.2014.0015 until December 20, 2014.

In the article "Cocaine Shifts the Estrus Cycle Out of Phase and Caffeine Restores It", Patricia Broderick, PhD and Lauren Malave, City College of New York, City University of New York Graduate Center, City University of New York, and NYU Langone Medical Center, New York, NY, show that cocaine shifts the estrus cycle, thereby changing a woman's estrogen levels. Caffeine can block these changes, suggesting that antagonists of the adenosine system may have a role in treating cocaine addiction.

"This is cutting-edge work that has never been shown before. It is critical knowledge relevant to women's reproductive health," says Patricia A. Broderick, PhD, Editor-in-Chief of Journal of Caffeine Research and Medical Professor in Physiology, Pharmacology & Neuroscience, The Sophie Davis School of Biomedical Education, The City College of New York, The City University of New York, and Adjunct Professor in Neurology, New York University Langone Medical Center and Comprehensive Epilepsy Center.

###

About the Journal

Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science is a quarterly journal published in print and online. The Journal covers the effects of caffeine on a wide range of diseases and conditions, including mood disorders, neurological disorders, cognitive performance, cardiovascular disease, and sports performance. Journal of Caffeine Research explores all aspects of caffeine science including the biochemistry of caffeine; its actions on the human body; benefits, dangers, and contraindications; and caffeine addiction and withdrawal, across all stages of the human life span from prenatal exposure to end-of-life. Tables of content and a sample issue may be viewed on the Journal of Caffeine Research website at http://www.liebertpub.com/jcr.

About the Publisher

See more here:

Caffeine counters cocaine's effects on women's estrus cycles

PUBLIC RELEASE DATE:

20-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

New Rochelle, NY, November 20, 2014-Women are more sensitive to the effects of cocaine and more susceptible to cocaine abuse than men. Cocaine's ability to disrupt a woman's estrus cycle may explain the sex differences in cocaine addiction, and new evidence that caffeine may be neuroprotective and able to block cocaine's direct effects on the estrus cycle reveals novel treatment possibilities, according to an article published in Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Journal of Caffeine Research website at http://online.liebertpub.com/doi/full/10.1089/jcr.2014.0015 until December 20, 2014.

In the article "Cocaine Shifts the Estrus Cycle Out of Phase and Caffeine Restores It", Patricia Broderick, PhD and Lauren Malave, City College of New York, City University of New York Graduate Center, City University of New York, and NYU Langone Medical Center, New York, NY, show that cocaine shifts the estrus cycle, thereby changing a woman's estrogen levels. Caffeine can block these changes, suggesting that antagonists of the adenosine system may have a role in treating cocaine addiction.

"This is cutting-edge work that has never been shown before. It is critical knowledge relevant to women's reproductive health," says Patricia A. Broderick, PhD, Editor-in-Chief of Journal of Caffeine Research and Medical Professor in Physiology, Pharmacology & Neuroscience, The Sophie Davis School of Biomedical Education, The City College of New York, The City University of New York, and Adjunct Professor in Neurology, New York University Langone Medical Center and Comprehensive Epilepsy Center.

###

About the Journal

Journal of Caffeine Research: The International Multidisciplinary Journal of Caffeine Science is a quarterly journal published in print and online. The Journal covers the effects of caffeine on a wide range of diseases and conditions, including mood disorders, neurological disorders, cognitive performance, cardiovascular disease, and sports performance. Journal of Caffeine Research explores all aspects of caffeine science including the biochemistry of caffeine; its actions on the human body; benefits, dangers, and contraindications; and caffeine addiction and withdrawal, across all stages of the human life span from prenatal exposure to end-of-life. Tables of content and a sample issue may be viewed on the Journal of Caffeine Research website at http://www.liebertpub.com/jcr.

About the Publisher

Read the rest here:
Caffeine counters cocaine's effects on women's estrus cycles